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Abstract
PIWIL2, a member of PIWI/AGO gene family, is expressed in the germline stem cells (GSCs) of testis for gametogenesis but
not in adult somatic and stem cells. It has been implicated to play an important role in tumor development. We have
previously reported that precancerous stem cells (pCSCs) constitutively express Piwil2 transcripts to promote their
proliferation. Here we show that these transcripts de facto represent Piwil2-like (PL2L) proteins. We have identified several
PL2L proteins including PL2L80, PL2L60, PL2L50 and PL2L40, using combined methods of Gene-Exon-Mapping Reverse
Transcription Polymerase Chain Reaction (GEM RT-PCR), bioinformatics and a group of novel monoclonal antibodies. Among
them, PL2L60 rather than Piwil2 and other PL2L proteins is predominantly expressed in various types of human and mouse
tumor cells. It promotes tumor cell survival and proliferation in vitro through up-regulation of Stat3 and Bcl2 gene
expressions, the cell cycle entry from G0/1 into S-phase, and the nuclear expression of NF-kB, which contribute to the
tumorigenicity of tumor cells in vivo. Consistently, PL2L proteins rather than Piwil2 are predominantly expressed in the
cytoplasm or cytoplasm and nucleus of euchromatin-enriched tumor cells in human primary and metastatic cancers, such as
breast and cervical cancers. Moreover, nuclear PL2L proteins are always co-expressed with nuclear NF-kB. These results
reveal that PL2L60 can coordinate with NF-kB to promote tumorigenesis and might mediate a common pathway for tumor
development without tissue restriction. The identification of PL2L proteins provides a novel insight into the mechanisms of
cancer development as well as a novel bridge linking cancer diagnostics and anticancer drug development.
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Introduction
A major obstacle for cure of cancer is that we still do not
sufficiently understand how a cancer is initiated and progressed,
despite the revived cancer stem cell (CSC) hypothesis [1,2,3,4].
Recently we have identified and established several clonal
precancerous stem cell (pCSC) lines (Lin
-CD44
+CD24
-) from
murine lymphoma, which have the potential of both benign and
malignant differentiation, depending on environmental cues
[1,5,6]. The identification of pCSCs suggests that pCSCs are a
precursor of CSCs [1]. Both pCSCs and CSCs, which are
considered to represent two developing stages of tumor stem cells
(TSCs) [1,3,4], can serve as tumor vasculogenic progenitor cells
(TVPCs) [6,7]. The existence of pCSCs has been functionally and
clinically verified in the murine mammary carcinoma [8] and
human leukemia [9] as well as intestinal precancerous lesions
[10,11,12]. Through the study of pCSCs, we have found that the
transcripts of germline stem cell (GSC) gene PIWIL2 are
constantly expressed in pCSC lines, but not in normal bone-
marrow (BM)-derived stem/progenitor cells [5], suggesting that it
may play an important role in TSC development [1,3,4].
The PIWIL2 (piwi-like 2: alias hili in humans or mili in mouse) is
a member of PIWI/AGO gene family [13], located at human
chromosome 8 and mouse chromosome 14, respectively, with
23 exons coding 973 amino acids (110 kDa of MW) with about
88.77% homologous between humans and mice in gene sequence
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=PIWIL2).
PIWI/AGO proteins contain Piwi and PAZ domains, having
multiple biological functions on GSC self-renewal, cell cycling,
RNA interference (RNAi), epigenetic modulation, and chromatin
remodeling in various organisms [14,15,16]. Four members of
PIWI or AGO subfamily have been identified in human genome
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of PIWI subfamily are mainly expressed in the testis or embryonic
tissues, and are essential for stem cell self-renewal such as in
Drosophila [17] and gametogenesis in mammals [18,19,20]. The
AGO subfamily is ubiquitously expressed in the embryonic and
adult tissues [13,18,21,22], mediating RNAi via forming two
types of RNAi complex: RNA-induced gene silencing complex
(RISC) and RNA-induced initiation of transcriptional gene
silencing (RITS) complex [14,23,24,25,26,27]. The former
mediates post-transcriptional gene silencing through activating
RNase activity and cleaving the RNA [24,28,29,30], and the
latter is required for transcriptional gene silencing and/or
chromatin remodeling [15,16,26,31].
Among PIWI subfamily members, PIWIL2 might play unique
roles in tumor development, although the underlying mechanisms
are largely unknown [1,3,4,5,21]. The PIWIL2 is silenced in adult
somatic and stem cells [1,5,21], but is widely expressed in various
types of cancers, including hematopoietic, cervical and breast
cancers [5,21,32,33,34,35]. Especially, it is stably expressed in
pCSCs [1,5], suggesting that it might play an important role in
tumor initiation and progression. Other members of PIWI
subfamily might also play roles in tumorigenesis [36,37]. Recently,
Piwil2 has been found to bind a novel class of small (26–30 nt)
RNA, which is named as piwi-interacting RNA (piRNA) or repeat-
associated small interfering RNAs (rasiRNAs), in mammal testis
[38,39,40,41,42,43]. It may silence selfish genetic elements, such
as retrotransposons, in the GSCs of testis [39,43,44]. Moreover,
Piwi proteins also mediate epigenetic activation through promot-
ing euchromatin histone modifications and piRNA transcription in
subtelomeric heterochromatin in Drosophila [15,16], suggesting that
Piwil2 may regulate tumor development epigenetically.
We have reported that knockdown of ‘‘Piwil2 mRNAs’’ by
Piwil2-specific small interference RNAs (siRNAs) significantly
reduced murine pCSC expansion in vitro [5]. However, overex-
pression of Piwil2 gene in BM cells cultured in the XLCM-
conditioned medium induced proliferation of the stem/progenitor
cells, changes in cell morphology, and formation of embryonic
body (EB)-like colonies, followed by apoptosis [5]. We refer to this
phenomenon as the proliferation- or transformation-associated cell
death (PACD or TACD), characterized by a timing difference
between cell proliferation and apoptosis. This delayed cell death
induced by exogenous Piwil2 is in contrast to the growth-
promoting or anti-apoptotic role of ‘‘Piwil2’’ that is spontaneously
expressed in pCSCs [5] or transiently expressed in NIH-3T3 cells
[21]. The contradictory observations suggest that Piwil2 either
plays a distinct role in pCSCs versus normal stem/progenitor cells
or itself is expressed in a different form.
In this study, we demonstrate that the ‘‘Piwil2’’ transcripts
expressed in pCSCs represent the transcripts of Piwil2-like (PL2L)
genes rather than Piwil2, as revealed by Piwil2-specific Gene-
Exon-Mapping Reverse Transcription Polymerase Chain Reac-
tion (GEM RT-PCR) in combination with bioinformatics and
biochemical analysis. Using monoclonal antibodies (mAbs), which
were generated in our laboratory and specific for a peptide
common to PIWIL2 and PL2L proteins of humans and mice, we
reveal that the PL2L genes encode at least four proteins, including
PL2L80, PL2L60, PL2L50 and PL2L40. Among them, PL2L60 is
predominantly expressed in pCSCs and various types of tumor cell
lines, including those derived from the blood, skin, soft tissues,
kidney, brain, breast, liver, pancreas, cervix, colon, ovarian, liver
and lung of humans and mice. PL2L60 appears to support cell
survival and proliferation through up-regulating Stat-3 and Bcl-2
genes, promoting transition of G0/1 to S-phase of cell cycle and
enhancing nuclear expression of RelA, a member of NF-kB
(nuclear factor kappa-light-chain-enhancer of activated B cells)
family. Overexpression of PL2L60 in human breast cancer cell
lines promoted their tumorigenesis at the initial or latent stage of
xenograft tumor formation. While PL2L proteins can be widely
detected in the euchromatin-enriched proliferating tumor cells in
primary and metastatic cancers, such as breast and cervical
cancers, PIWIL2 was detected mainly in apoptotic or apoptosing
cells. Moreover, PL2L proteins are always co-expressed with NF-
kB/RelA in the cytoplasm or nucleus, suggesting that PL2L60, in
cooperation with NF-kB, may play important but opposite roles to
Piwil2 in tumor development. The identification of PL2L proteins
provides a novel insight into the mechanisms of cancer
development as well as a novel target bridging cancer diagnostics
and anticancer drug development.
Results
Precancerous stem cells do not express full length Piwil2
transcripts
In order to solve the contradictory function between the
spontaneously expressed Piwil2 in pCSCs and transduced-Piwil2
in normal stem/progenitor cells [5], we investigated whether the
difference is caused by the dose of Piwil2 gene or its variants in
these cells. We designed a pair of primers to detect full length
Piwil2 transcripts in pCSCs by RT-PCR. The primers could
amplify full length Piwil2 transcripts in the testis, but unexpectedly,
failed to do so in the murine pCSC lines, including 2C4, 3B5C
and 3B6C [5] (Fig. 1A). The result suggested that a Piwil2 gene
variant(s) might be expressed in the pCSCs. To estimate the length
of Piwil2 transcripts [5], we performed GEM RT-PCR, which
could detect both full length Piwil2 transcripts and its potential
variants. We designed four pairs of Piwil2-specific primers which
cover full length Piwil2 transcript containing 23 exons. Each
primer pair spanned at least one intron (Fig. 1B & supplementary
Table S1). The upstream of each pair of primers overlapped with
the downstream of the previous one. As shown in Figure 1C, exons
1–7 were amplified neither in 3 clonal pCSC lines (2C4, 3B5C and
3B6C) [5] nor in a hematopoietic cancer stem cell (CSC) line
(clone 326T) [1]. In addition, exons 21–23 were also not amplified
in pCSCs (Fig. 1C). This was not caused by the inability of these
two primers to amplify corresponding exons, because each of the
four primer pairs was able to amplify corresponding Piwil2 exons
in the same sample of murine testis used in Fig. 1A (Fig. 1C & D).
As expected, no Piwil2 transcripts were detected from the freshly
isolated splenocytes (Fig. 1C). In agreement with the previous
report [5], the primers Pmili, which is specific for exons 18–21
(E18-21) of murine Piwil2 and was routinely used in our laboratory
for the detection of ‘‘Piwil2’’ mRNA in pCSCs and other tumor
cell lines, reproducibly amplified the ‘‘Piwil2’’ mRNA in the pCSC
lines (Fig. 1C). These results suggest that the gene products
amplified by the primers Pmili may not necessarily represent full
length Piwil2 transcripts and that ‘‘Piwil2’’ mRNAs detected by
this primer pair in the pCSCs might represent a Piwil2 variant(s),
likely truncated at the 59-end (Fig. 1D).
Identification of Piwil2-like (PL2L) genes and proteins in
the testis and tumor cell lines but not in normal tissues
Current data have shown that human PIWIL2 gene containing
23 exons is significantly larger than an average human gene
(Fig. 2A). Different exon usage often leads to production of spliced
mRNA variants, and differential promoter utilization inside a gene
often results in the formation of related but functionally distinct
proteins. These mechanisms greatly expand the coding capacity of
a gene. Therefore, we reasoned that PIWIL2 gene might use these
Piwil2-Like Proteins in Tumor
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To identify potential Piwil2 variants, we first used the software
Gene2Promoter from Genomatix Software Inc. (Ann Arbor, MI)
to analyze human and mouse PIWIL2 genes in order to find
potential promoters inside these genes. The results showed that
there are six potential promoters inside the PIWIL2 gene of
humans or mice (Fig. 2A). Among these promoters, five promoters
can be identified as the transcriptional initiators of PIWIL2,
PL2L60, PL2L50, PL2L40 and PL2L42, respectively, in humans or
mice (Fig. 2A). The promoter of PL2L60 is located in the region
that starts from inside the intron 10 and includes most sequence of
Exon 11 (Fig. 2A). This promoter initiates the transcription of
PL2L60 mRNA that can be translated into 60 kDa protein
PL2L60, in which PAZ domain is defective (Fig. 2B & 2C). The
predicted PL2L60 mRNA is confirmed by transcribed sequence
AK027497 from Genbank. The promoter of PL2L50 is located
inside the intron 13 (Fig. 2A), which transcribe PL2L50 mRNA
covering exons 14 to 23 (Fig. 2B) and its protein product contains
Piwi domain truncated at N-terminus (Fig. 2C). The predicted
PL2L50 is confirmed by transcribed sequence AK163647 (murine)
from Genbank. The promoter of PL2L42 is located at the region
that starts from inside the intron 14 and includes entire Exon 15
(Fig. 2A). This promoter initiates the transcription of PL2L42
mRNA that might be translated into a 42 kDa protein PL2L42,
which is only a part of Piwi domain truncated at N-terminus
(Fig. 2B & 2C). The predicted PL2L42 mRNA is supported by
transcribed sequence AK001213 from Genbank. The promoter of
PL2L40 is located inside the intron 12 (Fig. 2A). It initiates the
transcription of PL2L40 gene, which contains exons from 13 to 20
and two additional exons within the intron between exons 20 and
21. The PL2L40 contains a C-terminus truncated Piwi domain
(Fig. 2B & 2C). The predicted PL2L40 mRNA is confirmed by
transcribed sequence XM_942053 in Genbank. These predicted
mRNAs are all truncated at the 59-end, resulting in a defect or
absence of PAZ domain (Fig. 2C). The mRNA sequences of
human PL2L60, PL2L50, PL2L40 and PL2L60 and murine
PL2L50 can be found in Genbank.
To verify the protein expression of these PL2L genes in humans
and mice, we designed a C-terminal Piwil2 peptide with amino
acid sequence (15-mers) between PAZ and Piwi domains, which is
shared by Piwil2 and putative PL2L proteins as well as
homologous between the humans and mice. We immunized two
rabbits with the peptide to generate polyclonal antibody (pAb)
specific for Piwil2 and PL2L proteins. We obtained a high titer of
peptide-specific rabbit pAb from one of the rabbits (RB9926),
which was purified by the specific peptide-affinity chromatography
and further characterized by Western-blot. As shown in Fig. 3A,
the purified pAb can recognize a number of protein bands with
estimated molecular weight (MW) of 110, 80, 60, and 50 kDa in
both murine testicular cell lysates (Fig. 3A) and human tumor cell
Figure 1. pCSC lines do not express full length Piwil2 transcripts. A, pCSCs did not express full length Piwil2 (mili) transcripts. For RT-PCR
analysis, murine pCSC lines (2C4, 3B5C and 3B6C) [5] and murine tumor cell line (EL-4) were harvested at log phase of growth; bone marrow-derived
dendritic cells of mice (BMDC) were prepared as described [63] and harvested at day 11 of culture; and murine testis was harvested from male B6
mice. Full length mili mRNA was amplified by primers P1-mili-forward and P4-mili-reverse (Table S1). E18-21: transcripts of mili exons 18–21. B,
Diagram of the primers used for Piwil2-specific GEM RT-PCR. C, Products of GEM RT-PCR. SPL: freshly isolated splenocytes from male B6 mice. D,
Diagram of the results in ‘‘C’’. Dotted lines indicate that the exons were not transcribed by corresponding primers. The star markers ‘‘*’’ indicates that
transcripts E21-23 sometimes were detectable in 2C4, 3B5c, and 3B6C cells. P: primers; E: exons. Pmili: the primer pair previously used in our laboratory
to detect mouse Piwil2 transcripts (E18-21) [5].
doi:10.1371/journal.pone.0013406.g001
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because 110 and 50 kDa protein bands were not detected in the
testicular cell lysates of mili
2/2 mice [18] and the 80 and 60 kDa
protein bands were greatly reduced compared to wild-type (wt)
mice (Fig. 3A). Consistently the same protein bands in the human
tumor cell lysates were almost completely blocked by Piwil2
peptides, which were used as immunogens (Fig. 3B). The results
suggested that the Piwil2-specific polyclonal antibody at least
recognize three Piwil2-like proteins (PL2L80, PL2L60, and
PL2L50). Among them, PL2L80 could not be predicted from
NCBI GeneBank or Genomatix database (http://www.genomatix.
de/). Incomplete disruption of PL2L80 and PL2L60 proteins in
the mili
2/2 testis appeared to be associated with the expression of
transcripts covering Piwil2 exons from 6 to 23, which were not
abrogated at all in mili
2/2 testis, as well as with the low level
expression of Piwil2 exons from 1 to 7 in mili
2/2 mice, as
demonstrated by Piwil2-specific GEM RT-PCR (Fig. 3C),
although the underlying mechanism is not yet clear. In the
mili
2/2 mice, Piwil2 was disrupted via homologous recombination
with the 5.2-kb BamHI fragment encompassing from exon 2 to
exon 5 in the pPNT vector with a neomycin resistance cassette
[18]. Thus, the transcripts of PL2L genes or transcripts of Piwil2
truncated at 59 end, which were controlled by other independent
promoters, were not completely suppressed in mili
2/2 testis
(Fig. 2). The results suggest that whole Piwil2 protein, but not its
variants such as PL2L80 and PL2L60, are completely disrupted in
the mili
2/2 mice.
Although the gene sequence of PL2L80 was not found in the
gene banks so far, we have successfully cloned PL2L80, which
appears to utilize the same promoter as full length PIWIL2 does
(unpublished data). Characterization of PL2L80 gene is ongoing in
our laboratory.
PL2L60 is predominantly expressed in precancerous stem
cells
To determine the expression profiles of Piwil2 and PL2L
proteins in pCSCs, the pCSC lines (clone 2C4, 3B5C and 3B6C)
were analyzed by Western-blotting. As shown in Fig. 4, each
pCSC line expressed a high level of PL2L60, but little PL2L50 and
no Piwil2. As a negative control, no PL2L60 was detected in
splenocytes (Fig. 4A & B). Moreover, no Piwil2 and PL2L proteins
were detected in other tissues of normal mice, either by Western-
blotting or RT-PCR (supplementary Fig. S1), consistently with
others’ reports [13,18,21]. Interestingly, the level of PL2L60
protein in the pCSCs was 3.5,7.0 times more than that in 326T
cells, a hematopoietic CSC line that was established and cloned in
our laboratory ([1] & unpublished data). Compared to the
background in normal splenocytes, PL2L60 protein was dramat-
ically increased by 56.6 to 120 times in the pCSCs but only by
17.2 times in 326T cells (Fig. 4B). Interestingly, 326T cells were
Figure 2. Diagram of PIWIL2 and PL2L genes as well as their transcriptional and translational products. A, Schematic depiction of the
genomic structure of PIWIL2 and PL2L genes. Five potential promoters inside the PWIL2 gene were identified. The promoter PPiwil2 is responsible for
the transcription of Piwil2 mRNA in humans and mice, while other four promoters inside this gene, PPL2L60, PPL2L50, PPL2L42 and PPL2L40, may initiate the
transcription of PL2L60, PL2L50, PL2L42 and PL2L40 genes, respectively. Human PL2L60, PL2L42 and PL2L40 mRNAs, and mouse PL2L50 mRNA have
been identified in GenBank. The question marker ‘‘?’’ indicates that corresponding mRNA sequence has not been identified. B, Schematic
presentation of mRNA structure of PIWIL2 and PL2L genes. All variants are truncated at 59-end but all contain Piwil2 exons 15 to 23, except for PL2L40
which contains exons 13 to 20 and another two exons within the intron between exons 20 and 21 (red area in A&B ). C, Schematic structures of
Piwil2 and PL2L proteins. Compared to the full-length Piwil2 protein, all PL2L proteins are defective or absent of whole PAZ domain. Piwi domain is
normal in PL2L60 but defective in PL2L50, PL2L40 and PL2L42.
doi:10.1371/journal.pone.0013406.g002
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cells when they were cultured in vitro (Fig. 4C), probably associated
with the lower level of PL2L60. In parallel, more transcripts from
Piwil2 exon 18–21, amplified by Pmili, were detected in pCSC lines
than in 326T cells, but not in normal splenocytes (Fig. 1C: Pmili:
E18-21). These results implicated that ‘‘Piwil2’’ transcripts
expressed in pCSCs [5] de facto represent the transcripts of PL2L60.
PL2L60 up-regulates Stat-3 and Bcl-2 genes and
promotes pCSC expansion
Because PL2L60 was predominantly expressed in the pCSCs
(2C4, 3B5C and 3B6C) (Fig. 4), we reasoned that PL2L60 is
associated with pCSC expansion in vitro. In order to verify the
hypothesis, we knocked down PL2L60 mRNAs in pCSCs (clone
2C4) by transfection with siRNAs targeting exon 11 of Piwil2
transcripts. As a result, PL2L60 expression was reduced at both
transcriptional and translational levels in the siRNA-transfected
cells, as compared to the controls including the cells transfected
with scrambled siRNA (scRNA), mock transfected and un-
transfected (Fig. 5A, B & C). Correspondingly, pCSC expansion
was also significantly suppressed in the siRNA-transfected pCSCs
(Fig. 5D). The reduced pCSC expansion was associated with
down-regulation of the transcripts of Stat-3 and Bcl-2 genes but not
Bcl-XL gene in the pCSCs (Fig. 5E & F). The Piwil2 exon 11 is
located within the putative open reading frame of PL2L60 gene
(Fig. 2A). Consistently, the transcriptional products of both E6-14
and E18-21 were also significantly reduced in the pCSCs
transfected with siRNA targeting exon 11 (Fig. 5C). The results
reveal that the ‘‘Piwil2’’ mRNAs that was previously reported to
be stably expressed in pCSC lines [5] de facto represent the mRNAs
of PL2L60 gene, which can support pCSC expansion in vitro
through promoting Stat-3/Bcl-2 pathway.
PL2L60 is widely expressed in various types of human
cancer cells
To determine whether PL2L60 is also expressed in human
tumors, we examined PL2L60 expression in various types of
human cancer cell lines. As shown in Fig. 6A, PL2L60 was
predominantly expressed in cervical (HeLa) and breast cancer cell
lines (Fig. 6A). Among the breast cancer cell lines, MCF7 line that
usually grew slower in culture than MDA-MB-231 and MDA-MB-
468 (not shown) expressed lower level of PL2L60 proteins (Fig. 6B).
In contrast, long-term cultured primary human dermal fibroblasts
(HDF) expressed little PL2L60 proteins (Fig. 6A & B). In addition
to cervical and breast cancer cell lines, PL2L60 proteins were also
predominantly detected in other tumor cell lines derived from the
tumors of blood, skin, soft tissues, kidney, brain, breast, liver,
pancreas, cervix, colon, ovarian, liver and lung. The tumor types
involved include leukemia, lymphoma, adenoma, adenocarcino-
ma, carcinoma, melanoma, sarcoma, neuroblastoma, hepatoma,
insulinoma and endothelioma (supplementary Fig. S2 & Table S2).
The results suggest that PL2L60 is widely expressed in various
types of cancers without restrictions of tissue origin and tumor
types. In addition, Piwil2, PL2L80 and PL2L50 were also detected
in low levels or not detected at all in these lines with great variation
between lines as well as between individual experiments (Fig. 3 &
Fig. S2). The results suggest that the levels of PL2L proteins
expression in the cancer cell lines might be affected by culture
conditions, but PL2L60 is always predominantly expressed.
PL2L60 promoting tumorigenesis is associated with
increased nuclear NF-kB expression
Since PL2L60 could promote pCSC proliferation in vitro ([5] &
Fig. 5), we examined whether it also promoted human tumor cell
Figure 3. Identification and characterization of PL2L proteins of humans and mice. A & B, Western blot analysis of Piwil2 and PL2L
proteins expressed in mouse testis (A) and HeLa cells (B), using rabbit polyclonal antibody to Piwil2 peptide. A, Testicular cell lysates of mili
2/2 and
mili
+/+ mice. B, HeLa cell lysate: Lane 1 & 5: 4 mg/mL antibody without peptide; Lane 2 & 6: 4 mg/mL antibody with 16 mg/mL Peptide; Lane 3: 2 mg/
mL antibody alone; Lane 4: 2 mg/mL antibody with 8 mg/mL Peptide. P: Piwil2 peptide; Ab: antibody to Piwil2 peptide. C, GEM RT-PCR analysis of
testicular tissues from wild-type (Lane 1) and mili
2/2 mice (Lane 2): the primer pairs specific for E1-7, E6-14, E13-21 and E21-23 of Piwil2 were used for
GEM RT-PCR analysis, and the primer pair specific for E18-21 was used as a positive control. Lane 3: no cDNA control.
doi:10.1371/journal.pone.0013406.g003
Piwil2-Like Proteins in Tumor
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human breast cancer cell lines (MDA-MB-231) (Fig. 6C). As a
result, the proliferation of the MDA-MB-231 cells was also
significantly inhibited after knocking down PL2L60 mRNAs
(Fig. 6D), confirming that PL2L60, like in murine pCSCs, can
also support cancer cell proliferation in vitro. To further confirm
the function, we generated stable PL2L60-expressing cancer cell
lines by transducing human PL2L60 gene into MDA-MB-231 cells
(Fig. 7 & Fig. S3). The PL2L60-transduced cells demonstrated
significant increase in the entry of cycling cells from G0/1 into S-
phase, as compared to GFP-transduced control cells. This was
consistent with increased cell expansion in vitro (Fig. 7A & B).
Moreover, the increased cell expansion was associated with
enhanced expression of nuclear NF-kB (RelA/p65), a protein
complex that controls the transcription of genes including those
responsible for cancer cell survival and proliferation [45,46,47]
(Fig. 7C). While NF-kB was strongly detected in the cytoplasm but
weakly in the nucleus of the GFP-transduced cells, almost all of the
PL2L60-transduced cells expressed a high level of NF-kB in both
cytoplasm and nucleus. The cell size of PL2L60-transduced cells
was obviously increased compared to that of GFP-transduced cells,
suggesting an enhanced cell growth (Fig. 7C). It should be noted
that ,1% of cells expressed stronger cytoplasmic and nuclear NF-
kB in both samples of PL2L60-transduced and GFP-transduced
cells (Fig. 7C: arrows). The significance of the rare population is
warranted to be investigated further.
To determine the tumorigenic capacity of the PL2L60-
transduced tumor cell line, we transplanted PL2L60- and GFP-
transduced MDA-MB-231 cells into CB17 SCID mice, respec-
tively. The tumor nodules formed by PL2L60-transduced cells
were palpable as early as one week after transplantation, whereas
GFP-transduced control cells did not form palpable tumor nodules
at this time (Fig. 7D & E). Interestingly, the tumor nodules were
regressed three weeks later, but recurred with a tumor growth rate
comparable to that of GFP-transduced cells (Fig. 7D & E). At the
end of experiments, both PL2L60- and GFP-transduced tumors
were GFP-positive as detected by live imaging (not shown). The
result suggests that PL2L60 could promote tumorigenesis at the
initiating stage of xenograft tumor formation.
Piwil2 and PL2L proteins are differentially expressed in
human primary and metastatic cancers
To determine whether PL2L60 was also predominantly
expressed in native cancers in addition to tumor cell lines, we
attempted to generate murine monoclonal antibody (mAb) to
Piwil2 and PL2L60 or other PL2L proteins. Because polyclonal
Piwil2-peptide specific antibody recognizes both Piwil2 and PL2L
proteins (Fig. 3A & B), we used the same strategy to generate
mAbs to Piwil2 and PL2L proteins. Although we could not obtain
a mAb exclusively detecting PL2L60, we have established one
mAb specifically recognizing Piwil2 (clone Kao1) and two mAbs
recognizing both Piwil2 and PL2L proteins (clones Kao2 and
Kao3). As shown in Fig. 8A, the mAb Kao1 reacted with
,110 kDa proteins in the murine testis, but not any proteins in the
cancer cell lysates from human colorectal cancer cell line SW480
[48]. In contrast, mAbs Kao2 and Kao3 reacted strongly with
,110 kDa and,40 kDa proteins in the murine testis and
,60 kDa and ,50 kDa proteins in the cancer cell lysates. In
addition, mAbs Kao2 and Kao3 reacted weakly with ,80 kDa,
,60 kDa and ,50 kDa proteins in the testis of mice, and
Figure 4. PL2L60 rather than Piwil2 is predominantly and stably expressed in pCSC lines. A, The cell lysates of 2C4, 3B5C, 3B6C, 326T and
splenocytes freshly isolated from B6 mice were analyzed by Western blotting, with rabbit anti-Piwil2 antibody. B, The ratio of PL2L60 to b-actin (AU)
was determined using Image J software (NIH) and the folds of increased PL2L60 in each cell line relevant to normal splenocytes are shown in number
at the top of each column. AU: arbitrary unit. C, Comparison of cell viability between 2C4 and 326T colonies in cultures. The 2C4 and 326T cells
(1610
4/well) were cultured in 24-well plates, and the cell colonies were examined and taken as micrographs under Zeiss inverted microscope at day 5
of culture (original: x200). Note that apoptotic 326T cell in cultures were easily discerned under microscope compared to 2C4, 3B5C and 3B6C. Shown
is one representative colony of 2C4 and 326T, respectively, with apoptosing and apoptotic cells [2C4: 4/32 (12.5%); 326T: 11/18 (61.1%)]. 3B5C and
3B6C cells had the viability similar to 2C4 (not shown). An arrow indicates a representative apoptosing cell with condensed nucleus in the 2C4 colony.
doi:10.1371/journal.pone.0013406.g004
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(Fig. 8A). The different strength of the proteins bands likely
reflected different levels of the proteins in the murine testis and
human cancer cell line. Thus, mAbs Kao2 and Kao3 can
recognize Piwil2, PL2L80, PL2L60, PL2L50 and PL2L40,
similarly to the proteins recognized by Piwil2 peptide-specific
pAb, except for PL2L40 (Fig. 3B). Again, PL2L60 was
predominantly expressed in the colon cancer cell lines as detected
by mAbs Kao2 and Kao3 (Fig. 8A).
Then, we used the mAbs Kao1 and Kao2/3 (thereafter referred
to as Kao2) to examine the expression of Piwil2 and PL2L proteins
in the tissue microarray (TMA) cores of human breast (n=300)
and cervical cancers (n=100) or in some tissues sections of the
cancers. As shown in Fig. 8, only 1.67% of breast cancer TMA
cores (5/300) and 3% of cervical TMA cores (3/100) were stained
by mAb Kao1 (Fig. 8E), in which Piwil2 (Kao1)-expressing cells
were usually low in frequency (Fig. 8B); in contrast, all TMA cores
of cervical and breast cancers were stained by mAb Kao2 (Fig. 8B).
However, the frequency of the positively stained cells varied
between individuals (Fig. 8 & not shown). While Kao1
+ cells
displayed condensed nuclei, an apparent feature of apoptosing or
apoptotic cells in morphology (Fig. 8B1 & B3), the Kao2
+ cells
exhibited large nuclei enriched with euchromatin, a feature of cell
proliferation (Fig. 8B2 & B4). The tumor cells with a high level of
heterochromatin were either negative or faintly positive for PL2L
proteins (Fig. 8B2, compare the nuclei between Kao2
+ and Kao2
-
Figure 5. PL2L60 promotes pCSC expansion in vitro through up-regulation of Stat3 and Bcl2 gene expressions. The pCSCs (clone 2C4)
were transfected with Piwil2 exon 11-specific siRNA or scRNA, mock transfected (Mock), or untransfected (Untr), as previously described [5] and
analyzed for PL2L60 expression, gene expression and cell expansion. A, Western blot analysis of PL2L60 in pCSCs treated as described above. B,
Quantitation of PL2L60 proteins (AU) detected in A. C, RT-PCR analysis of Piwil2 transcripts in pCSCs using primer pairs specific for E6-14 or E18-21. D,
The effects of PL2L60 on pCSC expansion: pCSCs were counted as mean 6 SD in triplicate at indicated times after transfection with siRNA. **, p,0.01;
as compared to the mock or scRNA transfected groups. E, RT-PCR analysis of transcriptional expression of Stat3, Bcl2 and Bcl-xL genes in pCSCs: H2O
indicates that cDNA was omitted. F, Quantitation of Stat3, Bcl-2 and Bcl-xL transcripts (AU) shown in E. For Western blot (A & B) and RT-PCR (C, E & F)
analysis, the cells were harvested at 36–48 h after transfection; for cell expansion, the cells were counted at various time points post transfection as
indicated. The cells were seeded in triplicate as previously described [5]. AU (Arbitrary Units) was determined by the ratio of a factor tested to b-actin.
The data shown are a representative from at least 3 experiments.
doi:10.1371/journal.pone.0013406.g005
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Kao2 mAb mainly in cytoplasm (pattern: C) or in both cytoplasm
and nucleus (pattern: C-N) (Fig. 8B2, pattern C indicated by red
arrow; and pattern C-N indicated by green arrows). In the
metastatic cancer, all tumor cells were Kao2-positive, whereas
only a few of apoptotic or apoptosing Kao1
+ cells were
occasionally detected regardless of the locations (lymph nodes or
connective tissue) of tumor cells (Fig. 8C). The results suggest that
Piwil2 is mainly expressed in apoptotic or apoptosing tumor cells,
whereas PL2L proteins were expressed in euchromatin-enriched
proliferating and metastatic cancer cells. Thus, Kao2 and Kao3
mAbs could be used for detection of both primary and metastatic
cancers.
Because PL2L60 could promote breast cancer cell proliferation
in vitro, and overexpression of PL2L60 was associated with
increased nuclear NF-kB expression in tumor cell lines (Fig. 7),
we further investigated whether the expression of PL2L60 or PL2L
proteins was also associated with NF-kB expression in primary and
metastatic cancers. Breast cancer tissue sections were co-stained
with murine mAb (Kao2) to PL2L proteins and rabbit mAb to
RelA/p65, a subunit of NF-kB. Both PL2L proteins and p65 were
detected in the cytoplasm and nucleus of primary (Fig. 8D) and
metastatic cancers (not shown). Almost all the Kao2
+ cells were co-
stained by mAb to p65 regardless of C or C-N patterns (Fig. 8D3);
although the ratio of Kao2 (brown) to p65 (pink) was individually
different (not shown). Importantly, nuclear NF-kB expression
appeared to be dependent on nuclear PL2L proteins expression,
because p65 or PL2L proteins alone were not detected in the
nucleus of tumor cells (Fig. 8D4; yellow arrows indicate double
stained nuclei), despite the fact that variable levels of nuclear p65
were detected in a few nuclei of infiltrated inflammatory cells
(Fig. 8D4; green arrows). Nuclear Kao2
+p65
+ cells were about 24
610.58% among all Kao2
+p65
+ tumor cells (ranging from 9.09%
to 42.42% per tumor nest; n=16). Given the roles of NF-kBi n
tumorigenesis [45,46,47], the results suggest that nuclear
Kao2
+p65
+ tumor cells might play a critical role in tumor
development.
Discussion
We and others have reported that Piwil2 proteins or Piwil2
transcripts were detected in various types of cancers or cancer cell
lines [1,3,5,21,34,35,49,50]. While exploring the mechanism
underlying Piwil2-mediated tumor development, we found by
GEM RT-PCR that the ‘‘Piwil2’’ transcripts expressed in the
murine pCSCs were truncated at 59-end and absent of first 6 exons
of Piwil2. Through bioinformatics analysis of human and mouse
PIWIL2 gene, we found several potential 59-end truncated variants
of PIWIL2, called Piwil2-like (PL2L) genes. Based on the
information, we generated novel polyclonal and then monoclonal
antibodies to a peptide shared by Piwil2 and PL2L proteins of
humans and mice and identified four PL2L proteins, including
PL2L80, PL2L60, PL2L50, and PL2L40, in the testis and cancer
cell lines of humans and mice. Interestingly, PL2L60, instead of
Figure 6. PL2L60 is predominantly expressed in human tumor cells, promoting their expansion in vitro. A&B ,PL2L60 expression in
human breast and cervical cancer cell lines. Breast (MDA-MB-231, MDA-MB-468, and MCF-7) and cervical (HeLa) cancer cell lines and primary human
dermal fibroblasts (HDFs) were cultured in 6-well plates (2–3610
5/well), harvested when they grew confluent, and examined for PL2L60 expression
by Western blotting, using rabbit pAb to Piwil2 (A). The PL2L60 in A was normalized to b-actin and quantified (B). Shown is a representative of three
experiments. Numbers at the top of each column in B indicate the increased folds of PL2L60 in breast and cervical cancer cell lines, as compared to
HDFs. C&D :PL2L60 promoted human cancer cell expansion in vitro. MDA-MB-231 cells were transfected in triplicate in 6-well plates with human
Piwil2 exon 21-specific dicer substrate RNA duplexes (siRNA) or scrambled RNA duplexes (scRNA), or mock transfected for 48 h. The cells were
harvested, counted and analyzed by RT-PCR for Piwil2 E18-21 mRNA expression. C, Results of RT-PCR. D, Cell numbers (mean + SD in triplicate). The
data shown are a representative from three experiments.
doi:10.1371/journal.pone.0013406.g006
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pCSCs and various types of human and mouse tumor cell lines,
including those of leukemia, lymphoma, adenoma, adenocarcino-
ma, carcinoma, melanoma, sarcoma, neuroblastoma, hepatoma,
which were derived from various types of organs and tissues such
as blood, skin, soft tissues, kidney, brain, breast, liver, pancreas,
cervix, colon, ovarian, liver and/or lung. The finding strongly
suggests that PL2L60 is widely expressed in tumor cells regardless
of tumor types and tissue origins. Consistent with the observations
from cancer cell lines, PL2L proteins were also predominantly
expressed in primary and metastatic cancers; whereas Piwil2 were
essentially undetectable except in some apoptotic or apoptosing
cells. Because PL2L60 is predominantly expressed in cancer cell
lines, it is likely that PL2L proteins detected by the mAbs Kao2/3
in primary and metastatic cancers actually are PL2L60. The
results reveal that PL2L60 rather than Piwil2 are constitutively
and widely expressed in various types of cancers without the
restriction of tissue origin. The notion is also supported by the fact
that Piwil2 transcripts were undetectable in the bladder cancers by
real-time RT-PCR with the primers amplifying first 6 exons of
PIWIL2 [51], which are absent in PL2L genes. Therefore, the
‘‘Piwil2’’ transcripts amplified by primers within PL2L genes and
the translated proteins detected by mAbs Kao2/3, de facto
represent PL2L genes and PL2L proteins in cancer cell lines or
in the tissues of primary and metastatic cancers. The mAb Kao1
can be used to specifically identify Piwil2 and distinguish what are
detected by Kao2/3 from Piwil2. It should be noted that almost all
metastatic cancer cells were detected by mAb Kao2, suggesting
Figure 7. PL2L60 promoting tumorigenesis of human cancer cells is associated with the enhanced cell cycle transition from G0/1 to
S phase and increased nuclear NF-kB expression. Breast cancer cell lines (MDA-MB-231) were stably transduced with Lenti-PL2L60 or Lenti-GFP
viral vectors, cloned and analyzed for their cell cycling, expansion and tumorigenic capacity in CB17 SCID mice. A&B ,PL2L60 promoted the cell
cycle transition from G0/1 to S-phase and cell expansion. PL2L60-transduced and GFP-transduced stable cell lines were cloned and analysis for cell
cycle (A) and cell expansion (B). The data of three experiments shown in A are derived from a representative clone of PL2L60-transduced (Clone C5)
and GFP-transduced breast cancer cell lines (clone C6C2); and % of S-phase was also summarized in B. The number of cells cultured in 6-well plates
(5610
4/well) was enumerated at day 5 of culture and summarized in B. **, p,0.01; as compared between the PL2L60-transduced and GFP-
transduced cell lines. C, NF-kB (RelA/p65) expression in PL2L60-transduced (231-PL2L60) and GFP-transduced breast cancer cells (231-GFP), as
revealed by ICC staining (original magnification: x 400). D&E ,Enhanced tumorigenic capacity of 231-PL2L60 cells at the initial stage or latent phase
of xenograft tumor formation. D, Shown are the tumor growth curves of 231-PL2L60 and 231-GFP cells in CB17 SCID mice (n=3/group). E, Living
images which were taken at the time as indicated by an arrow in D: An arrow indicates weak GFP signal at the site injected with GFP-231. The data
shown are a representative of two reproducible experiments. GFP: 231-GFP; PL2L60: 231-PL2L60. **, p,0.01, as compared between two groups.
doi:10.1371/journal.pone.0013406.g007
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with NF-kB. A, Characterizing mouse mAbs to Piwil2-peptide shared by Piwil2 and PL2L proteins of humans and mice. The supernatants of mAbs
(clone Kao1, Kao2, and Kao3; 1:10 dilution) were used to Western-blot mouse testicular lysates and human colon cancer cell line SW480 lysates. Kao1
specifically reacted with Piwil2 (,110 kDa) but not with PL2L proteins in the testis. The faint bands detected by mAb Kao1 in SW480 reflected non-
specific binding of secondary antibody, because (a) similar bands were observed in the absence of primary antibody (no mAb control); (b) no
corresponding bands were observed in the testicular lysates; and (c) they were not matched with known PL2L protein bands blotted by Kao2 and
Kao3 mAbs. Note that Kao2 and Kao3 reacted with Piwil2, PL2L80, PL2L60, PL2L50 and PL2L40, and the different intensity between them reflected
their variable amounts in the relevant samples. B, PL2L proteins but not Piwil2 are predominantly expressed in primary breast and cervical cancers.
TMAs of breast cancer (n=300) and cervical cancer (n=100) or regular sections (breast cancer: n=3; cervical cancer: n=5) were stained with mAb to
Piwil2 (Kao1) or PL2L proteins (Kao2 or Kao3). Shown are representative micrographs of Piwil2 (B1 & B3) and PL2L proteins expression (B2 & B4) in the
primary breast (B1 & B2) and cervical cancers (B3 & B4). Arrows in B1 and B3 indicate the Piwil2-expressing (mAb Kao1
+) apoptotic or apoptosing cells
enlarged in the insets. The inset in B2 shows a tumor cell enriched with heterochromatin was faintly stained by mAb Kao2, while other two cells
enriched with euchromatin were strongly stained by mAb Kao2 in cytoplasm but faintly in nuclei. The tumor cells in the inset were enlarged from
those indicated by a red arrow in B2. In addition, green arrows in B2 indicate the C-N pattern of mAb Kao2
+ cells. Magnification of the micrographs:
B1 and B4: x 75; B3, x150, and B2, x300. C, PL2L proteins but not Piwil2 are expressed in all metastatic tumor cells. Shown are representative
micrographs of Piwil2 (C1 & C3) and PL2L proteins expression (C2 & C4) in the metastatic cancer cells in tissue stroma (C1 & C2) and in lymph nodes
(C3 & C4). Arrows in C1 indicate Piwil2 (mAb Kao1)-negative metastatic tumor cells in the stroma; and arrows in C3 indicate apoptosing tumor cells
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cancers. Taken together, we have identified a novel protein
PL2L60, which is widely expressed in various types of cancers and
might have the potential to be used as a common cancer
biomarker. Other PL2L proteins such as PL2L80, PL2L50 and
PL2L40 need to be characterized further.
Obviously, PL2L60 is not limited to be expressed in pCSCs [5].
It was also detected in various types of cancer cell lines.
Knockdown of PL2L60 mRNAs in murine pCSCs or human
breast cancer cells significantly suppressed their expansion in vitro.
In agreement, over-expression of PL2L60 in the breast cancer cell
lines led to their increased expansion in vitro. The mechanisms
underlying the increased expansion appear to be mediated by
reduced programmed cell death (PCD) because of enhanced
expression of Bcl-2 and Stat3 genes and promoted G0/1 R S-phase
in cell cycle by PL2L60. This is further supported by the increased
expression of nuclear NF-kB in the PL2L60-transduced cell lines.
NF-kB is a ubiquitous transcription factor that controls the
expression of genes involved in immune response, cell survival,
apoptosis, and cell cycle. Given the fact that NF-kB is inactivated
in cytosol complexed with the inhibitory protein IkBa but
activated by ubiquitination of IkBa, shuttling to nucleus, only is
nuclear NF-kB considered to be functional [45,46]. Nuclear
translocation of NF-kB may up-regulate prosurvival factor Bcl-2 in
tumor cells, as observed in human hepatoma cells [52]. Thus, the
increased nuclear NF-kB expression in the nuclei of PL2L60-
transduced cells may lead to increased cell expansion through up-
regulating cell survival genes Stat-3 and Bcl-2 and promoting cell
cycling (Fig. 9).
The in vitro findings are supported by in vivo observations that
PL2L60-transduced human breast cancer cells formed palpable
tumor nodules rapidly within first few weeks after transplanted into
CB17 SCID mice, while GFP-transduced cells were at the latent
period of tumorigenesis. Usually it takes at least two to three
months (latent phase) to form palpable xenograft tumors, which
are supposed to be mediated by rare numbers of CSCs in the
context of freshly isolated tumor cells or tumor cell lines ([1,4,53]
& unpublished observation). The formation of tumor nodules by
PL2L60-transduced cells at the latent phase suggests that they
proliferated faster in vivo than GFP-transduced cells did. Moreover
in primary and metastatic cancers of humans, the exclusive
expression of PL2L60 or PL2L proteins in the euchromatin-
enriched tumor cells also suggests that the PL2L60-expressing cells
are highly active or proliferative [32,33], which contributes to
enhanced tumor growth.
However, it is puzzling that PL2L60-expressing tumor nodules
regressed three weeks later and then recurred soon with a
comparable growth rate to GFP-transduced tumor cells. This
might be the combined effects of the rapid growth and high
susceptibility to innate anticancer immunity of the PL2L60-
overexpressing tumor cells in SCID mice. However, PL2L60-
overexpressing CSCs, like GFP-expressing CSCs, were resistant to
innate immune cells, and thus be responsible for tumor
recurrence. In contrast, GFP-transduced tumor cells are less
proliferative and thus could not form tumor nodules at the latent
phase. The hypothesis needs further verification. Taken together,
PL2L60 expression can promote the tumorigenic capacity of
tumor cells through promoting cell survival and proliferation in
cooperation with NF-kB.
How does PL2L60 cooperate with NF-kB in modulating tumor
development? It has been reported that Piwi proteins can promote
euchromatin histone modifications and piRNA transcription in
subtelomeric heterochromatin in Drosophila [15,16]. The fact that
co-expression of PL2L proteins with NF-kB exclusively in the
euchromatin-enriched tumor cells suggests that PL2L60 could
promote the functions of NF-kB through modulating chromatin
structure or chromatin modifications [54], although precise
mechanisms need to be elucidated further (Fig. 9).
Another important observation inthis study is that inprimary and
metastatic cancers, nuclear PL2L proteins-expressing tumor cells are
always co-expressed with nuclear NF-kB/p65 (nPL2L
+p65
+). Since
expressing Piwil2 (mAb Kao1) in the lymph node. Magnification of micrographs: C1, x150; C2, C3 and C4: x400. D, Co-expression of PL2L proteins
(mAb Kao2) with NF-kB in tumor cells. Shown are representative micrographs of single and double color IHC staining of serial sections of breast
cancer. The serial sections were prepared from an invasive ductal carcinoma infiltrated by inflammatory cells. The serial sections were stained by
mouse mAb Kao2 alone (D1: brown; x150), rabbit mAb to p65 alone (D2: pink; x150) or mAb Kao2 followed by mAb to p65 (D3: brown and pink; 150).
Note that the infiltrated inflammatory cells are negative for PL2L proteins as shown in D1 but positive for p65 as shown in D2. The box in D3 is
projected to D4 (x600). Arrows in D4 indicate the tumor cells doubly stained by mAb Kao2 and mAb to p65 in the nuclei. E, Summarized data of IHC
stained TMAs of breast cancer (n=300) and cervical cancer (n=100). Shown are the percentages of breast and cervical cancers, respectively,
expressing Piwil2 or PL2L proteins.
doi:10.1371/journal.pone.0013406.g008
Figure 9. The hypothetical mechanisms underlying PL2L60
promoting tumorigenesis. PL2L60 can promote tumor cell growth
through interaction with NF-kB. Migration of PL2L60 from cytoplasm to
nucleus may promote nuclear localization of NF-kB. In the nucleus,
PL2L60 might promote the transcriptional activity of NF-kB through
remodeling chromatin structure, resulting in enhanced transcription of
genes for cell survival, cell cycling and cell growth. This model might
lead us to identification of novel signaling pathways specific for tumor
cell survival and proliferation.
doi:10.1371/journal.pone.0013406.g009
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+p65
+ cells were detected in various stages of breast cancers
with individual variation in frequency (data not shown), quantitation
of PL2L
+p65
+ cells in tumor tissues may predict the outcome of
tumor progression or regression. It has been reported that NF-kB
canbind thepromotersofprogression-associated genesinmelanoma
[47]; NF-kB has been shown to play important roles in tumor stem
cells [45,46]; and nuclear localization of NF-kB appears to be
associated with the progression of prostatecancers[55]. Therefore,it
is likely that the nuclear PL2L
+p65
+ tumor cells might represent
tumor stem cells. Further characterization of nuclear PL2L
+p65
+
tumor cells is warranted for fully understanding of their relationship
to tumor stem cell [4].
The broad goal of cancer research is to identify and characterize
common developmental pathway for tumors, as it is critical for
developing a safe and cost-effective therapeutic strategy for cancer
[1,3]. However, we are still far away from the goal. Although
cancer genes have been extensively investigated for decades, most
of them discovered so far are cancer-contributing genes, including
oncogenes (ONGs), tumor suppressor genes (TSGs) and stability
genes (SGs) rather than cancer-causing genes [56,57]. These genes
are converged to several signaling pathways, which are required as
well for the normal control of cell survival and cell growth and thus
dispensable for tumor development [57]. No cancer-causing gene
has been identified so far [57]. An urgent need for cancer research
community is to discover such kind of genes that are unique but
common for the development of various types of cancer [3,4,57].
A cancer-causing gene should be silenced in normal adult cells but
can be activated throughout the process of tumor initiation,
progression and invasion without tissue restriction [1,3,4]. Like the
ONG and TSG of cancer-contributing gene family [57], cancer-
causing gene may be classified into tumor-barrier gene and tumor-
initiating gene [3,58]. Such kind of genes can override the function
of cancer-contributing genes and their products can be used as
common biomarkers for detection and intervention of cancers.
Discovery of cancer-causing genes is currently a major challenge
to cancer research [3,4,57]. Tumor stem cell (TSCs), which are
supposed to undergo developmental process from tumor-initiating
stem cells (TISCs) to pCSCs and CSCs [1,3,4,59], are an ideal
target for searching of cancer-causing genes, because their
developing status is critical for tumor initiation, progression and
invasion or metastasis [1,3,4]. Through the study of pCSCs, we
have realized that Piwil2 and PL2L proteins might play important
but distinct roles from ONGs, TSGs and SGs in tumor
development. Piwil2 and PL2L proteins have the potential to
serve as tumor-barrier gene and tumor-initiating gene, respectively
[3]. Therefore, we propose that a cancer can develop from a
lengthy process of benign proliferation R precancer R cancer,
which is mediated by TISCs, pCSCs and CSCs, respectively; and
the process might be controlled and/or modulated by Piwil2 and
PL2L proteins. The functions of Piwil2 and PL2L proteins might
override those of cancer-contributing genes. In addition to Piwil2
and PL2L proteins, other GSC and embryonic stem cell genes
might be the potential candidates of cancer-causing genes
[1,3,4,59]. Should the hypothesis be proven, Piwil2 and PL2L
proteins not only can be used as a common biomarker for tumor
but also a target for the development of new anticancer drug.
Materials and Methods
Ethics Statement
Human specimens of cervical and breast cancer were remnant
tissues derived from Tissue Archives material at Department of
Pathology and provided by the Tissue Procurement Shared
Resource (TPSR), Comprehensive Cancer Center, Ohio State
University (OSU). The Archive material protocol, the informed
consent and patient information forms were reviewed and
approved by the Institutional Review Board (IRB), OSU. Each
patient signed the consent form. The exemption protocol for this
study was reviewed and approved by the Institutional Review
Board (IRB), OSU (Protocol number: 2007EC686). Animal
experiments were conducted based on Animal Use Protocols
approved by the Institutional Animal Care and Use Committee
(IACUC), OSU (Protocol number: 2006A0250).
Mice, cell lines, and reagents
Male C57BL/B6 (B6) mice, CB17 SCID mice and mili
2/2 B6
mice were used at the age of 8–12 wk. The mili
2/2 mice, which
were obtained from Dr. Haifan Lin’s laboratory [18], were bred
and maintained in the animal pathogen-free facility at The Ohio
State University Medical Center. The hematopoietic pCSC lines
2C4, 3B5C and 3B6C were cloned from a mouse with dendritic
cell-like leukemia and characterized as previously described [5].
The hematopoietic CSC line (clone 326T) was developed in our
laboratory ([1] & unpublished). EL-4 thymoma cells were
maintained in our laboratory. Primary human dermal fibroblasts
(HDFs) that were obtained from foreskin were obtained from Dr.
Andrew Issekutz’s laboratory. Cervical cancer cell line HeLa,
breast cancer cell lines MD-MB-231, MD-MB-468, and MCF-7
were obtained from Dr. Sanford Barsky’s laboratory, Other tumor
or immortalized cell lines used in this study are listed in
supplementary Table S2, which were obtained from Dr.
Quansheng Zhou’s laboratory except for where indicated. All
the hematopoietic tumor cell lines were maintained in R10F
(RPMI 1640 plus 10% fetal calf serum supplemented with 5 mM
glutamine, 50 mM 2-mecaptoethonal, 100 U/ml penicillin, and
100 mg/ml streptomycin) [5], and non-hematopoietic tumor cell
lines were maintained in D10F (Dulbecco’s Modified Eagle
Medium [DMEM] with the same supplements as in R10F) in
our laboratory or co-author’s laboratories for the cooperative
experiments of this study. All cell lines were harvested at log phase
of growth for RT-PCR or Western blot analysis.
RT-PCR
RT-PCR was performed as previously described [5,6]. Total
RNA was extracted from cell lines or de novo isolated testicular cells
and splenocytes. The cDNA was generated by reverse transcrip-
tion using Superscript II ( Invitrogen, CA) and oligo (dT) in a 20 ml
reaction containing 1 mg of total RNA, which was pretreated with
RNase-free DNase I (Invitrogen, CA) to eliminate contaminating
genomic DNA. Briefly, an aliquot of 0.5 ml cDNA was used in
each 20 ml PCR reaction, using PCR Master Mix (Promega, Ca).
The following conditions were used: an initial denaturation at
95uC for 5 min followed by denaturation at 94uC for 30 seconds,
annealing at 65uC for 1 min, touchdown 21uC per cycle, and
extension at 72uC for 1 min for a total of 10 cycles. Then the
condition was fixed for 25 cycles of denaturation at 94uC for 30
seconds, annealing at 50uC for 1 min, and extension at 72uC for
1 min with a final extension at 72uC for 10 min. PCR products
were analyzed by 1.5% agarose gel. The sequence of primers is
listed in the supplementary Table S1.
Gene-Exon-Mapping Reverse transcription polymerase
chain reaction (GEM RT-PCR)
To identify Piwil2 variants, we designed four primer pairs
specific for murine Piwil2 and three pairs for human PIWIL2,
which cover the entire Piwil2 transcripts containing 23 exons of
mice or humans and span the whole coding sequence. Each
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Ensembl (http://www.ensembl.org). The upstream of each pair of
primers overlapped the downstream of previous one. The primers
used for GEM RT-PCR are listed in supplementary Table S1. All
primers were designed using PrimerQuest (http://www.idtdna.
com/).
RNA interference (RNAi) Assay
RNAi assay was performed on murine pCSCs and human
breast cancer cell lines, as previously described [5]. All siRNAs was
purchased from the Integrated DNA Technologies (IDT, Coral-
ville, IA). The murine pCSC cells were transfected with murine
Piwil2-specific small interference (si) RNA (UCGUACCUACC-
GAAUCGAU), which targets exon 11 of Piwil2 within the open
reading frame of PL2L60, or scrambled (sc) small RNA (scRNA)
(CACGUGAGGAUCACCAUCA). The transfection was per-
formed in 24-well plates with a siRNA transfection kit following
the manufacturer’s instruction (Qiagen). For the effect of Piwil2
exon 11-specific siRNA on cell expansion, a low density of
transfected cells (100/well) was seeded and counted at indicated
times. For RT-PCR analysis of PL2L60, a high density of
transfected cells (1610
6/well) was seeded and harvested at
36,48 h of culture and analyzed using primers specific for Piwil2
exon 6–14 (E6-14) and exon 18–21 (E18-21), respectively (Table
S1). For RNAi experiments on human cancer cell lines, breast
cancer cells MD-MB-231 were seeded overnight in triplicate at 2.5
– 3.0610
5/well in 24-well plates and transfected with serum-free
DMEM medium mixed with transfection reagents and 100 pmol
human Piwil2 exon 21-specific dicer substrate RNA duplexes of 25
nucleotide in length (sense strand: 59CUAUGAGAUUCCUCAA-
CUACAGAAG; antisense strand: 59 CUUCUGUAGUUGAG-
GAAUCUCAUAGUU), or universal negative control dicer-
substrate duplex (DS Scrambled Neg) [60]. Transfection reagents
and RNA duplexes were mixed and incubated in serum-free
DMEM medium for 60 min before adding into culture plates.
Generation of rabbit polyclonal and murine monoclonal
antibodies to Piwil2 and PL2L proteins
Polyclonal antibody to Piwil2 was generated in collaboration
with Abgent Inc. Briefly, two New Zealand Rabbits were
immunized each with 100,200 mg KLH-conjugated Piwil2
peptides (503 IPEKMKKDFRAMKDL 517) with a sequence
common to humans and mice emulsified in the Complete Freund’s
Adjuvant (CFA) for twice in a two weeks interval, and then with
100 mg peptide/rabbit in the Incomplete Freund’s Adjuvant (IFA)
at week 4. Starting from week 5, the rabbits were immunized with
100 mg peptide/rabbit in PBS every week until week 9, and were
bled for 20,30 ml every week until sacrificed at week 10. About
100 ml serum per rabbit was collected and rabbit IgG was purified
by protein A/G chromatography followed by peptide-affinity
chromatography. The titer and specificity of antibody was
determined by competitive ELISA and Western-blot.
For generation of murine mAbs to Piwil2 and PL2L proteins,
two BALB/c mice were immunized with the same peptide for
rabbit polyclonal antibody in CFA, 100 mg per mouse, followed by
boosting with 50 mg/mouse every week until the required titer was
reached. Spleen cells from the mouse with best titer were fused
with myeloma cell F0 by adding 1.5ml PEG 1500 per 3610
8
mixed cells. Growing fused hybridoma clones were screened
against antigen (such as free peptide) for test of their specificity and
sensitivity. ELISA positive clones were tested by appropriate
applications such as Western-blotting. Selected clones from this
test were subcloned at least two times.
Western blot
Cell lysates and tissue extracts were mixed with equal volume of
SDS-sample buffer (50 mM Tris-HCl, pH 7.4, 5 mMEDTA, 5%
SDS, 20% glycerol, 10 mM DTT, 0.05% Bromophenol Blue) and
heated at 95uC for 3 min. The proteins in samples were resolved
on a 4,20% gradient Tris-glycine acrylamide gel and transferred
to a nitrocellulose membrane. After blocking with 5% milk-TBS-
Tween 20, immunoblotting was performed using either rabbit
polyclonal anti-Piwil2 peptide antibody (IgG) or murine mono-
clonal anti-Piwil2 peptide antibody (IgM), or rabbit-anti-b-actin
antibody. Following development with the appropriate species-
specific horseradish peroxidase-conjugated anti-immunoglobulin
antibodies and SuperSignal chemiluminescence substrate, the
bands were visualized on X-ray film.
Construction of lentiviral PL2L60 vector (pLenti6-
ZsGreen-PL2L60)
To construct the lentiviral expression vector expressing PL2L60,
a pair of primers, 59-GCG GAT CCA CCA TGG CTG ATG
GGA AAG AGA TCA CAT TCT-39 (sense) and 59-GAG AAT
TCA CAG GAA GAA CAG GTT CTC G-39 (antisense), was
used to amplify the cDNA coding for PL2L60 gene by PCR. The
full-length human Piwil2 cDNA in plasmid pBluescriptR (cDNA
clone MGC:26732 IMAGE:4826162) purchased from ATCC
(Manassas, VA) was used as the template. The synthesized
PL2L60 cDNA from PCR, which has a BamHI site in 59 end
and an EcoRI site in 39 end derived from the primers, was cloned
into the lentiviral vector pLenti6-ZsGreen, which is derived from a
recombination of the Zoanthus sp. green fluorescent protein
(ZsGreen) (Clontech) and pLenti6/V5-TOPO (Invitrogen), to
generate pLenti6-ZsGreen-PL2L60. The insert of PL2L60 was
verified by sequencing. Pseudotype pLenti6-ZsGreen-PL2L60 and
pLenti6-ZsGreen viruses were produced by transfecting the
293FT cell line, as instructed by manufacturer (Invitrogen). The
viral supernatants were harvested on 72 h post transfection.
Generation of stable cell lines overexpressing PL2L60
To generate cancer cell line overexpressing PL2L60, human
breast cancer cell line MDA-MB-231 were transduced with
lentiviral pLenti6-ZsGreen-PL2L60 (Lenti-PL2L60) or pLenti6-
ZsGreen viruses (Lenti-GFP), as previously described [5]. Briefly,
cells were seeded (2610
5/ well) in 24-well plate in complete
culture medium (D10F) and incubated overnight at 37uCi na
humidified 5% CO2 incubator. Then, the medium was removed
from the cultures and the Lenti-PL2L60 or Lenti-GFP viral
supernatant was added. After overnight incubation, the medium
containing viruses was replaced with fresh D10F. Fresh D10F
containing 10 mg/ml of Blasticidin was added 24 h later to select
stably transduced lines. The green fluorescent protein (GFP)-
expressing cells from 231-PL2L60 and 231-GFP lines were sorted
by flow cytometry, cloned by limiting dilution, and then
maintained in D10F, respectively.
Cell cycle assay
Cell cycle analysis of tumor cell lines was performed as
previously described with necessary modifications [61]. Briefly,
tumor cell lines were cultured in D10F in the 6-well plates to about
80% confluence, washed with serum-free DMEM for twice, and
continuously cultured in the serum-free medium for 16 h for cell
starvation. Then, the cells were recovered by addition of D10F.
Six hours later, the cells were harvested and washed with PBS,
fixed in 70% ethanol (10
6 cells/ml), and stored at 220uC until
being stained with propidium iodide (PI; 50 mg/ml) in PBS
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for 30 min at room temperature, and subjected to cell cycle
analysis using flow cytometry. The acquired data were further
analyzed using Modfit LT
TM (Verity Software House).
Xenograft tumor transplantation
SCID CB17 mice were injected s.c. with 5610
6 cloned 231-
PL2L60 or 231-GFP cell lines. Tumor incidence and size were
monitored once a week starting 1 wk after inoculation. Once
tumors were palpable, tumor size was measured twice a week. The
mice were sacrificed when one of the mice in any group developed
a tumor about 15,20 mm in diameter. At the early stage of tumor
formation and the end of experiments, living tumor images were
taken using Macro Imaging System (LT-9MARCOIMSYS;
Lightools Research).
Immunohistochemical (IHC) and immunocytochemical
(ICC) analysis
IHC analysis of human tumor specimens was performed as
previously described [5,6,32,33,62]. Tumor specimens of breast
and cervical cancers were fixed in formalin and embedded in
paraffin for pathological and immunohistochemical analysis, as
described. Tissue microarrays (TMAs) were built by the
Histological Core Facility, Department of Pathology. Serial
TMA or conventional tissue sections (4,5 mm) were stained by
H. & E. and a mouse mAb Kao1 (specific for Piwil2) or Kao2
(specific for Piwil2 and PL2L proteins) followed by a horseradish
peroxidase (HRP)-conjugated secondary antibody for pathological
and IHC analysis, respectively. The immunostained sections were
counterstained with hematoxylin. In some experiments, TMA
cores or conventional sections were double-stained with mouse
mAb Kao2 (supernatant; 1:3 dilution) and rabbit mAb to RelA/
p65 (1:100 dilution; Epitomics Inc.) in sequence. PL2L proteins
(brown) were developed by the detection kit Envision plus Dual
Link (Dako) and DAB chromogen, and p65 (pink) was revealed by
the detection kit Mach 4 (Biocare) and Fast Red chromogen. For
the double IHC staining control, serial sections were stained with a
single primary antibody of interest.
For ICC analysis, the tumor cells growing at log phase were
harvested, washed, and resuspended in 10% R10F (1–2610
6 cells/
ml). A mixture of 10 ml cell suspensions plus 190 ml PBS (1–2610
4
cells/200 ml/slide) was subjected to cytospin at 1000 rpm for 3
minutes. The slides were air-dried, rehydrated and stained with
rabbit mAb to p65, as described for IHC staining.
Statistical analysis
Data of multiple group observations were statistically analyzed
by the one-way analysis of variance (ANOVA), and two groups of
observations were compared by student-T test. A value of p#0.05
was considered significant. Data are represented as mean 6 SD. *,
p#0.05; **, p#0.01.
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